Pharmacogenomic Study (Adjuvant Chemotherapy)

Samsung Medical Center

Status: Completed

Conditions: Gastric Cancer

Study type: Observational

Funder types: Other

Identifiers

NCT01470404

2008-05-053

Details and patient eligibility

About

To assess the role of germline polymorphisms in xenobiotic metabolism genes in toxicity profile.

To assess the role of germline polymorphisms in genes associated with DNA repair, p53 tumor suppressor gene and angiogenesis pathway in predicting recurrence and survival in gastric cancer patients treated with adjuvant chemotherapy.

Enrollment: 792 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• gastric cancer patients treated with adjuvant chemotherapy

Exclusion Criteria:

Trial design

792 participants in 1 patient group

adjuvant chemotherapy

Description:

Patients enrolled on to the adjuvant XP trial + patients who received adjuvant chemotherapy following curative resection of gastric cancer